Stockscreener 앱 받기
172.97
2.34%
-4.14
시장 영업 전:
175.00
2.03
+1.17%
Biogen Inc 주식(BIIB)의 최신 뉴스
Biogen Inc. stock (US09062X1037): Does its neurology pipeline hold the key to renewed growth for U.S. investors? - AD HOC NEWS
Biogen to acquire Apellis for $5.6B to strengthen immunology portfolio - MSN
Biogen Inc. stock underperforms Friday when compared to competitors - MarketWatch
Biogen Inc (XSWX:BIIB)Valuation Measures & Financial Statistics - GuruFocus
Biogen Inc. stock (US09062X1037): Is the neurology focus strong enough to unlock new upside? - AD HOC NEWS
Today's Analyst Ratings Update for Biogen (BIIB): Key Changes | BIIB Stock News - GuruFocus
Today's Analyst Ratings Update for Biogen (BIIB): Key Changes | - GuruFocus
Biogen’s Alloy Antisense Deal Adds New Dimension To Genetic Medicine Bet - Sahm
Apellis Pharmaceuticals (APLS) hits 2-year high on 140% upside from Biogen merger - MSN
Biogen Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Boost for Cambridge as US company Alloy Therapeutics shows real Vigilance - Business Weekly
Is It Time To Reassess Biogen (BIIB) After Its 49% One Year Share Price Surge - simplywall.st
Biogen Inc. stock rises Wednesday, still underperforms market - MarketWatch
Biogen to use Alloy Therapeutics’ Anticlastic ASO platform - BioWorld News
Biogen (BIIB) Partners With Alloy Therapeutics on Antisense Drug Platform - MEXC Exchange
Biogen, Investors Reach Deal In Alzheimer's Drug Litigation - Law360
Biogen (NASDAQ: APLS) readies tender offer for Apellis under March 31, 2026 deal - Stock Titan
Biogen Inc. stock outperforms competitors on strong trading day - MarketWatch
Why Biogen (BIIB) could beat earnings estimates again - MSN
Biogen’s ASO Strategy: How a $27B Giant is Investing $100M in a New Platform - Bitget
Why Biogen (BIIB) Could Beat Earnings Estimates Again - Yahoo Finance
Alloy Therapeutics and Biogen Announce Multi-Target Collaboration - National Today
Biogen taps Alloy platform to push antisense drug pipeline forward - MSN
What Is Driving Biogen’s Recent Drop and What Comes Next - Trefis
Biogen (BIIB) Stock Signs ASO Platform Deal With Alloy Therapeutics - CoinCentral
Biogen Taps Alloy Platform To Push Antisense Drug Pipeline Forward - Benzinga
RBC Capital Adjusts Biogen Price Target to $213 From $233, Maintains Outperform Rating - marketscreener.com
Alloy Therapeutics Partners with Biogen on Multi-Target Collaboration - National Today
Avoiding Lag: Real-Time Signals in (BIIB) Movement - Stock Traders Daily
Biogen’s Apellis Deal And High Dose SPINRAZA Shift Growth Outlook - simplywall.st
Alloy Therapeutics enters into multi-target collaboration and license agreement with Biogen for use of Alloy's Anticlastic™ ASO platform - marketscreener.com
Alloy Therapeutics Enters Into Multi-Target Collaboration And License Agreement With Biogen For Use Of Alloy’S Anticlastic™ Aso Platform - TradingView
Alloy Therapeutics Enters into Multi-Target Collaboration and License Agreement with Biogen for Use of Alloy’s AntiClastic™ ASO Platform - Business Wire
Why Biogen (BIIB) May Surpass Earnings Projections Once More - Bitget
Why Biogen Stock Got Mashed on Monday - Yahoo Finance
Biogen (NASDAQ: APLS) files Form 3 on Apellis voting group status - Stock Titan
Biogen Discloses Tender Offer at Apellis with 14.2% Stake - TradingView
[SCHEDULE 13D] Apellis Pharmaceuticals, Inc. Major Shareholder Acquisition (>5%) - Stock Titan
Biogen Acquires Apellis Pharmaceuticals in $5.6 Billion Move into Immunology - FinancialContent
Biogen : to Report First Quarter 2026 Financial Results April 29, 2026 - marketscreener.com
Biogen to Report First Quarter 2026 Financial Results April 29, 2026 - Biogen
Idiopathic Membranous Nephropathy Market is Predicted to Reach USD 1 Billion by 2036 Due to Rising Therapeutic Options | DelveInsight - GlobeNewswire Inc.
Revisiting Eisai And Biogen's Leqembi Data For Alzheimer's Disease (NASDAQ:BIIB) - Seeking Alpha
Biogen Paid a 140% Premium for Apellis. Was the $5.6B Deal Worth It? - TIKR.com
Biogen Expects to Take $0.19 per Share Charge in Q1 - marketscreener.com
Biogen Inc. 8-K SEC Filing Details for April 6, 2026: Company Information, Stock, and Compliance Overview - Minichart
Biogen expects $34 million charge for research and development expenses By Investing.com - Investing.com India
Biogen expects $34 million charge for research and development expenses - Investing.com
BiogenExpects Q1 2026 GAAP and non-GAAP EPS impact of $0.19 from chargeSEC filing - marketscreener.com
Apellis Stock Soars After Biogen Deal, Momentum Score Surges—Here's What Shareholders Get - Benzinga
Biogen (NASDAQ: BIIB) projects $34M Q1 2026 in-process R&D expense - Stock Titan
Biogen Inc. (BIIB) stock price, news, quote and history - Yahoo Finance Singapore
Biogen Inc. (BIIBCL.SN) interactive stock chart - Yahoo Finance UK
BIIB (Biogen) 3-Year Revenue Growth Rate : -1.20% (As of Dec. 2025) - GuruFocus
Biogen’s Apellis Deal Reshapes Growth Outlook And Valuation Story - Yahoo Finance
Stifel Maintains Biogen(BIIB.US) With Buy Rating, Maintains Target Price $214 - Moomoo
15,051 Shares in Biogen Inc. $BIIB Bought by Element Squared LLC - MarketBeat
Biogen (NASDAQ: BIIB) plans tender offer to acquire Apellis (APLS); materials pending - Stock Titan
Biogen (BIIB) CAO Sean Godbout nets shares from RSU vesting and tax withholding - Stock Titan
Biogen to acquire Apellis in $5.6 billion deal - Ophthalmology Times
Biogen Inc stock: Plunges to $177.34 – What it means for you - AD HOC NEWS
Rx Rundown: Eli Lilly, Blackstone, Biogen and more - Medical Marketing and Media
Nisa Investment Advisors LLC Sells 9,121 Shares of Biogen Inc. $BIIB - MarketBeat
Weekly Buzz: SPRY Gains FDA Nod; EU Expands Kerendia Label; LLY Acquires CNTA; BIIB Snaps Up APLS - RTTNews
Biogen Inc. (BIIB) Stock Forecasts - Yahoo Finance
1.10%
0.21%
자본화:
|
볼륨(24시간):